In addition, ATIC, HPRT1, ASNS, SULT1A2, and HAL may represent attractive therapeutic targets for HER2-positive breast cancer, and require further validation studies, especially considering that treatment with specific inhibitors may alter the expression of these metabolic genes. This evidence concerns the gene ATIC and breast carcinoma.